Table 3 Direct costs for the 3-month study period for the total patient group (n = 192; in 2019 Euro)
Cost components | Mean costs | SD1 | Minimum | Median | Maximum | 95% CI | % of total direct costs | Estimated annual direct costs2 |
|---|---|---|---|---|---|---|---|---|
Total direct costs | 6452 | 7584 | 0 | 1920 | 29,182 | 5533; 7422 | 100 | 25,808 |
 Medication (n = 165) | 4953 | 6854 | 0 | 573 | 28,224 | 4087; 5876 | 76.8 | 19,812 |
  mTOR inhibitors* (n = 71) | 4358 | 6520 | 0 | 0 | 25,273 | 3448; 5342 | 67.5 | 17,432 |
  Antiseizure drugs (ASDs) (n = 123) | 415 | 1962 | 0 | 104 | 26,538 | 239; 706 | 6.4 | 1660 |
  Other prescription drugs (n = 104) | 132 | 385 | 0 | 8 | 2606 | 84; 186 | 2.0 | 528 |
  OTC drugs and supplements (n = 70) | 41 | 100 | 0 | 0 | 700 | 29; 54 | 0.6 | 164 |
  Emergency medication/medication on demand (n = 42) | 7 | 36 | 0 | 0 | 347 | 3; 13 | 0.1 | 28 |
 Hospitalization (n = 23) | 518 | 1691 | 0 | 0 | 11,487 | 312; 750 | 8.0 | 2072 |
 Outpatient treatment (n = 157) | 467 | 1156 | 0 | 194 | 15,097 | 352; 626 | 7.2 | 1868 |
 Diagnostics (n = 140) | 155 | 242 | 0 | 44 | 1691 | 124; 192 | 2.4 | 620 |
 Ancillary therapies (n = 54) | 125 | 307 | 0 | 0 | 2120 | 84; 174 | 1.9 | 500 |
 Auxillary material (n = 14) | 49 | 253 | 0 | 0 | 2235 | 18; 87 | 0.8 | 196 |
 Rehabilitation (n = 2) | 40 | 410 | 0 | 0 | 4983 | 0; 92 | 0.6 | 160 |
 Emergency service use (n = 9) | 44 | 217 | 0 | 0 | 1800 | 19; 75 | 0.7 | 176 |
 Specific diets (n = 3) | 9 | 97 | 0 | 0 | 1200 | 0; 23 | 0.1 | 36 |
 Transport costs (n = 25) | 5 | 17 | 0 | 0 | 130 | 3; 7 | 0.1 | 20 |
 Co-payments for therapies (n = 17) | 39 | 177 | 0 | 0 | 1400 | 19; 64 | 0.6 | 156 |
 Other co-payments (n = 45) | 48 | 183 | 0 | 0 | 1700 | 27; 75 | 0.7 | 192 |